Last reviewed · How we verify
Standard diuretic therapy
Standard diuretic therapy increases urine output and reduces fluid volume in the body by inhibiting sodium and water reabsorption in the kidneys.
Standard diuretic therapy increases urine output and reduces fluid volume in the body by inhibiting sodium and water reabsorption in the kidneys. Used for Hypertension, Edema associated with heart failure, liver cirrhosis, or renal disease, Congestive heart failure.
At a glance
| Generic name | Standard diuretic therapy |
|---|---|
| Sponsor | University of Parma |
| Drug class | Diuretic |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Diuretics work by blocking ion transporters in the nephron (loop of Henle, distal convoluted tubule, or collecting duct depending on class) to prevent reabsorption of sodium, chloride, and water. This reduces circulating blood volume and lowers blood pressure, making them useful for managing hypertension, edema, and heart failure. The specific mechanism varies by diuretic class (thiazide, loop, potassium-sparing, or osmotic).
Approved indications
- Hypertension
- Edema associated with heart failure, liver cirrhosis, or renal disease
- Congestive heart failure
Common side effects
- Hypokalemia (low potassium)
- Hyperuricemia (elevated uric acid)
- Hyperglycemia (elevated blood glucose)
- Hypotension (low blood pressure)
- Dehydration
- Electrolyte imbalances
Key clinical trials
- Spot Analysis of Natriuresis to Guide up- or Down-titration of Diuretic Therapy in Ambulatory Patients With Chronic Heart Failure (NA)
- Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure (NA)
- Hemodynamic Resuscitation Guided by Non-Invasive Mean Systemic Filling Pressure to Prevent Acute Kidney Injury in Septic Shock (NA)
- POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure (PHASE2, PHASE3)
- Focusing on the Menopausal Transition to Improve Mid-Life Women's Health (PHASE2, PHASE3)
- Transformative Research in Diabetic Nephropathy 2.0
- Colchicine Versus Placebo in Acute Myocarditis Patients (PHASE3)
- Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications in Acute-on-chronic Liver Failure. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard diuretic therapy CI brief — competitive landscape report
- Standard diuretic therapy updates RSS · CI watch RSS
- University of Parma portfolio CI